News
PAVMZ
0.1500
+49.85%
0.0499
BRIEF-Lucid Diagnostics Says Qtrly Loss Per Share $0.47
Reuters · 03/14 17:39
BRIEF-Lucid Diagnostics Provides Business Update And Q4 And Full Year 2022 Financial Results
Reuters · 03/13 22:27
BRIEF-PAVmed Says On Feb 14, Lucid Diagnostics Entered Into Agreement With ResearchDx
Reuters · 02/17 23:27
BRIEF-PAVmed And Lucid Diagnostics Provide Strategic Business Update
Reuters · 01/17 21:12
BRIEF-PAVmed Receives Notice From Nasdaq That Co Will Be Afforded Until June 27, 2023 To Regain Compliance
Reuters · 12/30/2022 21:28
BRIEF-Pavmed Partners With Novosound On Ultrasound Imaging Technology
Reuters · 12/22/2022 13:28
PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
NEW YORK, December 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that its majority-owned digital ...
Business Wire · 12/15/2022 13:25
BRIEF-PAVmed Provides Third Quarter 2022 Financial Results
Reuters · 11/15/2022 22:14
BRIEF-Lucid Diagnostics Inc Reports Quarterly Adjusted Loss Per Share Of $0.28
Reuters · 11/14/2022 22:21
Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results
NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided ...
Business Wire · 11/14/2022 21:40
PAVmed to Participate in BTIG Digital Health Forum
NEW YORK, November 11, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed", the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today announced that Lishan Aklog,...
Business Wire · 11/11/2022 13:25
Does PAVmed (NASDAQ:PAVM) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 08/17/2022 12:50
BRIEF-PAVmed Provides Business Update And Preliminary Q2 2022 Results
BRIEF-PAVmed Provides Business Update And Preliminary Q2 2022 Results
Reuters · 08/16/2022 22:10
PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
PAVmed press release (<span class="ticker-hover-wrap...
Seekingalpha · 08/16/2022 20:49
BRIEF-Lucid Diagnostics Reports Q2 GAAP Loss Per Share $0.41
BRIEF-Lucid Diagnostics Reports Q2 GAAP Loss Per Share $0.41
Reuters · 08/15/2022 20:48
Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
NEW YORK, August 15, 2022--Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Business Wire · 08/15/2022 20:25
Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio
NEW YORK, August 11, 2022--Lucid Diagnostics Inc. announced its subsidiary, LucidDx Labs Inc., launched four new Lucid Test Centers in California, Texas Florida and Ohio.
Business Wire · 08/11/2022 12:25
Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies
NEW YORK, August 04, 2022--Newly published AGA update supports esophageal precancer screening to prevent esophageal cancer using EsoGuard on samples collected with its EsoCheck.
Business Wire · 08/04/2022 12:25
PAVmed to Hold a Business Update Conference Call on August 16, 2022
NEW YORK, August 03, 2022--PAVmed Inc. announced that the Company will host a business update conference call on Tuesday, August 16, 2022, at 4:30 PM EDT.
Business Wire · 08/03/2022 12:25
PAVmed Chairman & CEO Lishan Aklog, M.D. Named to Savoy’s 2022 Most Influential Black Executives in Corporate America
NEW YORK, July 19, 2022--PAVmed's Chairman & CEO Lishan Aklog, M.D. was selected as one of the Most Influential Black Executives in Corporate America in 2022 by Savoy Magazine
Business Wire · 07/19/2022 12:25
More
Webull provides a variety of real-time PAVMZ stock news. You can receive the latest news about Pavmed Inc through multiple platforms. This information may help you make smarter investment decisions.
About PAVMZ
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.